UNSPSC 51182220: Dinoprost trometamol

This classification denotes a prostaglandin analogue, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CT6BBQ5A68. European Medicines Agency schedules Dinoprost trometamol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01758MIG. Dinoprost trometamol generally arises in the molecular formula C20H34O5.C4H11NO3. The term 'dinoprost trometamol' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule dinoprost trometamol under HS 29375000 and SITC 54156.

SMILES: CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)O)O)O)O.C(C(CO)(CO)N)O.

UNSPSC 51182220 Dinoprost trometamol is a Commodity code covering a specific pharmaceutical active ingredient used in veterinary and human medicine. State and local governments procure dinoprost trometamol and related generic multi-source pharmaceuticals through cooperative purchasing agreements to supply public health facilities, corrections systems, and other government-operated clinical settings. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body for recent activity under this code. Buyers in this space require manufacturers and wholesalers to maintain comprehensive compliance certifications—including current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) compliance—and to hold sufficient insurance coverage, including commercial general liability of $5,000,000 per occurrence and professional liability of $2,000,000. Products must meet FDA requirements with a minimum six-month shelf life and at least one year of expiration dating from manufacture.

MMCAP's multi-state cooperative purchasing vehicle serves participating state and local government facilities across Minnesota, Oregon, and other member jurisdictions. The most recent solicitation is MMCAP's Request for Proposal S1070000015802, issued January 20, 2026, with a response deadline of March 26, 2026, establishing multiple contracts for generic multi-source pharmaceuticals and over-the-counter products effective July 1, 2026. Proposals are evaluated primarily on price competitiveness (75 percent weight), with secondary scoring on fixed pricing for the contract term (10 percent), electronic data interchange (EDI) capability (5 percent), administrative fee compliance (5 percent), and administrative data format requirements (5 percent). Vendors must maintain contractual relationships with at least two of three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and agree to a 3 percent administrative fee on all purchases. The contract term is two years for new responders with optional extensions at MMCAP's discretion, or through June 30, 2028 for incumbent responders.